C Sixty Inc.
This article was originally published in Start Up
Executive Summary
C Sixty Inc. aims to find commercial applications for Buckminsterfullerene, a sixty-carbon atom (C60) molecule and only the third form of elemental carbon found in nature, at the intersection of nano- and biotechnologies. According to the company's CEO, Uri Sagman, these soccer ball-shaped and nanometer-sized Buckyballs have potential futures as therapeutics, drug delivery scaffolds, and components of medical devices and diagnostics. Furthest along in the C Sixty pipeline are an anti-HIV protease compound and a compound designed to treat neurodegenerative disorders.
You may also be interested in...
Shrinking Discovery
The theory that smaller is better--as it is has been in the computer industry--is now driving enthusiasm for nanotechnology, a term that refers to the process of manipulating materials at atomic scale. New players are crowding under this hot rubric, including many working at not nearly so small a scale. Drug discovery methods are among the most compelling near-term nano-applications, but start-ups face challenges like those met by micro-scale pioneers Affymetrix and Caliper. Firms must show they can physically create systems they describe, and that teeny discovery methods actually matter for bench scientists. Business models in this emerging sector reflect the difficulties of harnessing novel science in ways that will satisfy drugmakers who've become extra-tough customers under pressure to deliver commercial results in a shifting, financially depressed market. Some start-ups are working on a fee-for-service basis, on specific projects that address customers' immediate needs. Others are deliberately doing development work on their own, gathering data to attract partnerships that may prove all the more rewarding because of their measured starts.
Hijacking The Messenger
Recent excitement around exosomes underscores their potential to solve drug delivery challenges that have limited the power and applicability of the biopharma industry’s growing arsenal of therapeutic modalities.
CNS IPOs Follow Broad Industry Trends
Datamonitor Healthcare's five-year review of initial public offerings of CNS-focused companies shows that they held their own compared with other biopharma sectors. The markets rewarded pain and neurodegenerative disease-focused players in particular. Step-up multiples in CNS IPOs slightly outpaced those for other biotechs.